findmyKOL
Clinical trialNCT00276302CompletedPhase 1Interventional

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

SponsorInfinity Pharmaceuticals, Inc.Enrollment63Gastrointestinal Stromal TumorsSoft Tissue Sarcomas
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objectives of the study are: * Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies * Recommend a dose for subsequent studies of IPI-504
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Mount Sinai Hospital

    Toronto, Ontario, Canada

United States
  • Premiere Oncology

    Scottsdale, Arizona, United States

  • Premiere Oncology

    Santa Monica, California, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • University of Michigan Hosptials

    Ann Arbor, Michigan, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Retaspimycin Hydrochloride
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2005
Primary completion
30 Nov 2010
Completion
30 Nov 2010
Last update posted
6 Jan 2011
Registered enrollment
63
Registry id
NCT00276302
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.